* Enfusion Inc ENFN.N ENFN.K is expected to report
results on December 2.
* The Chicago Illinois-based company is expected to report
revenue of $26.724 million, according to the mean estimate from
5 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Enfusion Inc is for
earnings of 4 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* Wall Street's median 12-month price target for Enfusion Inc is
$26, about 24.6% above its last closing price of $19.61.
This summary was machine generated November 30 at 21:09 GMT.
All figures in US dollars unless otherwise stated